Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Glyxambi is a prescription tablet containing empagliflozin and linagliptin. It is used with diet and exercise to improve blood sugar control in adults with type 2 diabetes. Its two ingredients lower blood sugar through different mechanisms.
read more about glyxambi ...Empagliflozin increases the amount of glucose passed in urine. Linagliptin increases the activity of hormones that help regulate blood sugar after meals. Together, they help lower blood glucose in adults with type 2 diabetes.
Glyxambi is taken once daily in the morning, with or without food. The prescribed strength depends on the treatment plan. Kidney function and hydration status should be assessed before treatment and as clinically indicated.
Urinary tract infections and respiratory symptoms are among reported side effects. Genital yeast infections and dehydration can also occur. Seek prompt care for symptoms of ketoacidosis, a serious urinary infection, or severe persistent abdominal pain.
Glyxambi is not indicated for blood sugar control in type 1 diabetes. It may be unsuitable for some people with substantially reduced kidney function. A clinician may direct you to pause it before surgery or prolonged fasting.
It contains empagliflozin and linagliptin. They belong to different classes of diabetes medicines.
The label directs once-daily use in the morning. It can be taken with or without food.
It is not indicated for blood sugar control in type 1 diabetes. Its empagliflozin component can increase the risk of diabetic ketoacidosis in that setting.
The label advises withholding it for at least three days before surgery or procedures involving prolonged fasting, if possible. Follow the instructions from your treating clinician on stopping and restarting it.
Empagliflozin and linagliptin (oral route) - Side effects & dosage. Mayo Clinic. https://www.mayoclinic.org/drugs-supplements/empagliflozin-and-linagliptin-oral-route/description/drg-20137736. Date Accessed October 6, 2026.
Empagliflozin; Linagliptin Tablets. Cleveland Clinic. https://my.clevelandclinic.org/health/drugs/19588-empagliflozin-linagliptin-tablets. Date Accessed October 6, 2026.
Fixed-dose combination of empagliflozin and linagliptin for the treatment of patients with type 2 diabetes mellitus: A systematic review and meta-analysis. PubMed. https://pubmed.ncbi.nlm.nih.gov/32020696/. Date Accessed October 6, 2026.
Glyxambi. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/glyxambi. Date Accessed October 6, 2026.
GLYXAMBI- empagliflozin and linagliptin tablet, film coated. DailyMed (National Library of Medicine). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ddbab689-f76c-488c-9613-4168d41dd730. Date Accessed October 6, 2026.